Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with …

M Gatti, F Pea - Expert Review of Anti-infective Therapy, 2023 - Taylor & Francis
Introduction The choice of best therapeutic strategy for difficult-to-treat resistance (DTR)
Gram-negative infections currently represents an unmet clinical need. Areas covered This …
被引用次数：23 相关文章

Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with …

M Gatti, F Pea - EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023 - cris.unibo.it
Introduction: The choice of best therapeutic strategy for difficult-to-treat resistance (DTR)
Gram-negative infections currently represents an unmet clinical need. Areas covered: This …

Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with …

M Gatti, F Pea - Expert review of anti-infective therapy, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction The choice of best therapeutic strategy for difficult-to-treat resistance (DTR)
Gram-negative infections currently represents an unmet clinical need. Areas covered This …

Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with …

M Gatti, F Pea - 2023 - cabidigitallibrary.org
Introduction: The choice of best therapeutic strategy for difficult-to-treat resistance (DTR)
Gram-negative infections currently represents an unmet clinical need. Areas covered: This …